A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma

Annals of Oncology

Volumn 13, Issue 12, 2002, Pages 1935-1944

  Janinis, J ^a   McTiernan, A ^a   Driver, D ^a   Mitchell, C ^b   Cassoni, A M ^a   Pringle, J ^c   Kilby, A ^a   Whelan, Jeremy S ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

Dose intensive therapy; High dose chemotherapy; Metastatic osteosarcoma; Pelvic osteosarcoma; Poor prognosis osteosarcoma

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MAGNESIUM; MESNA; METHOTREXATE; POTASSIUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BRAIN DISEASE; CANCER CONTROL; CANCER RECURRENCE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; LUNG METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; OSTEOSARCOMA; PELVIS TUMOR; PERIPHERAL NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SEPSIS; SHORT COURSE THERAPY; STOMATITIS; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TISSUE NECROSIS; TREATMENT OUTCOME; VOMITING;

EID: 0036924420     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf338     Document Type: Article

References (35)

1. Eilber F, Giuliano A, Eckardt J et al. Adjuvant chemotherapy for osteosarcoma: a randomised prospective trial. J Clin Oncol 1987; 5: 21-26.
2. Link MP, Goorin AM, Horowitz M et al. Adjuvant chemotherapy of high grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin Orthop, 1991; 270: 8-14.
3. Rosen G, Marcove RC, Caparros B et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-2177.
4. Bramwell VH, Burgers M, Sneath R et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992; 10: 1579-1591.
5. Meyers PA, Heller G, Healey J et al. Chemotherapy for non-metastatic osteosarcoma: the Memorial Sloan Kettering experience. J Clin Oncol 1992; 10: 5-15.
6. Beron G, Euler A, Winkler K. Pulmonary metastases from osteogenic sarcoma: complete resection and effective chemotherapy contributing to improved prognosis. Eur Paediatr Haematol Oncol 1985; 2: 77-85.
7. Meyers P, Heller G, Healey JH et al. Osteogenic sarcoma with clinically detectable metastases at initial presentation. J Clin Oncol 1993; 11: 449-453.
8. Marina NM, Pratt CB, Bhaskar NR et al. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 1992; 70: 2722-2727.
9. Kellie SJ, Pratt CB, Parham DM et al. Sarcomas (other than Ewing's) of flat bones in children and adolescents. A clinicopathologic study. Cancer 1990; 65: 1011-1016.
10. Estrada-Aguilar J, Greenberg H, Walling A et al. Primary treatment of pelvic osteosarcoma. Report of five cases. Cancer 1992; 69: 1137-1145.
11. Bielack SS, Wulff B, Delling G et al. Osteosarcoma of the trunk treated by multimodal therapy: Experience of the Cooperative Osteosarcoma. Study Group. Med Ped Oncol 1995; 24: 6-12.
12. Malcolm AJ, Pringle J, Misdorp W et al. A reproducible method of assessing the post-chemotherapy changes in high grade clinical osteosarcoma. J Pathol 1988; 155: 342A (Abstr).
13. Franklin HR, Simonetti GP, Dubbelman AC et al. Toxicity grading system. A comparison between the WHO scoring system and the CTC when used for nausea and vomiting. Ann Oncol 1994; 5: 113-117.
14. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Picci P, Bacci G, Ferrari S, Mercuri M. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of the bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Ann Oncol 1997; 8: 1107-1115.
16. Bacci G, Picci P, Briccoli A et al. Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions). Tumori 1992; 78: 200-206.
17. Campanacci M, Bacci G, Bertoni F et al. The treatment of osteosarcoma of the extremities: twenty years' experience at the Instituto Ortopedico Rizzoli. Cancer 1981; 48: 1569-1581.
18. Huvos AG. Bone Tumors: Diagnosis, Treatment and Prognosis, 2nd edition. Philadelphia, PA: WB Saunders 1991.
19. Schajowicz F. Tumor and Tumor-like Lesions of the Bone: Pathology, Radiology and Treatment, 2nd edition. Berlin: Springer-Verlag 1995.
20. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997; 33: 1725-1731.
21. Souhami RL, Craft AW, Van der Eijken JW et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350: 911-917.
22. Meyers PA, Heller G, Healey JH et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11: 449-453.
23. Morgan E, Baum E, Bleyer WA et al. Treatment of patients with metastatic osteosarcoma: a report from the Children's Cancer Study Group. Cancer Treat Rep 1984; 68: 661-664.
24. Michelagnoli MP, Lewis IJ, Gattamaneni HR et al. Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma. Br J Cancer 1999; 79: 1174-1178.
25. Voute PA, Souhami RL, Nooij M et al. A phase II study of cisplatin, ifosfamide, and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. Ann Oncol 1999; 10: 1211-1218.
26. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-1608.
27. Patel SR, Vadhan-Raj S, Papadopoulos N et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies: dose response and schedule dependence. J Clin Oncol 1997; 15: 2378-2384.
28. Bacci G, Mercuri M, Briccoli A et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Cancer 1997; 79: 245-254.
29. Grimer RJ, Carter SR, Tillman RM et al. Osteosarcoma of the pelvis. J Bone Joint Surg Br 1999; 81B: 796-802.
30. Davis A, Bell R, Goodwin P. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994; 12: 423-431.
31. Miniero R, Brach del Prever A, Vassallo E et al. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma. Bone Marrow Transplant 1998; 22 (Suppl 5): S37-S40.
32. Chan KW, Petropoulos D, Choroszy M et al. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant 1997; 20: 1039-1043.
33. Lucidarme N, Valteau-Couanet D, Oberlin O et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant 1998; 22: 535-540.
34. Graham ML, Yeager AM, Leventhal BG et al. Treatment of recurrent and refractory solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue. J Clin Oncol 1992; 10: 1857-1864.
35. Sauerbrey A, Bielack S, Kempf-Bielack B et al. High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001; 27: 933-937.